Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$2.78 -5.8%	$3.39	$2.01 ▼ $5.64	$184.94M	1.74	1.13 million shs	870,846 shs
ELDN Eledon Pharmaceuticals	$3.27 -0.3%	$3.43	$2.00 ▼ $5.54	$195.81M	0.66	285,129 shs	61,884 shs
ONCY Oncolytics Biotech	$0.59 +3.8%	$0.60	$0.47 ▼ $1.53	$51.15M	1.07	526,553 shs	298,509 shs
VYGR Voyager Therapeutics	$3.59 +1.7%	$3.62	$2.75 ▼ $9.55	$198.57M	1.02	450,222 shs	249,076 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	-5.76%	-8.85%	-15.50%	-19.42%	-37.67%
ELDN Eledon Pharmaceuticals	-0.30%	-3.25%	-2.39%	-31.01%	+37.97%
ONCY Oncolytics Biotech	+3.84%	-1.05%	-1.35%	-18.70%	-45.70%
VYGR Voyager Therapeutics	+1.70%	+6.53%	-1.64%	-34.96%	-53.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.3213 of 5 stars	3.5	0.0	0.0	2.2	0.0	0.6
ELDN Eledon Pharmaceuticals	2.206 of 5 stars	3.5	2.0	0.0	3.5	1.7	0.0
ONCY Oncolytics Biotech	1.5716 of 5 stars	3.5	3.0	0.0	1.6	0.0	0.0
VYGR Voyager Therapeutics	4.5956 of 5 stars	4.6	1.0	4.6	2.2	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	3.00	Buy	$11.67	319.66% Upside
ELDN Eledon Pharmaceuticals	3.00	Buy	$12.50	282.26% Upside
ONCY Oncolytics Biotech	3.00	Buy	$4.33	632.11% Upside
VYGR Voyager Therapeutics	3.11	Buy	$13.97	289.03% Upside

Current Analyst Ratings Breakdown

Latest ONCY, ELDN, CRDF, and VYGR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/13/2025	VYGR Voyager Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $12.00
3/13/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
3/12/2025	VYGR Voyager Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$12.00 ➝ $10.00
3/12/2025	VYGR Voyager Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/12/2025	VYGR Voyager Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/10/2025	ONCY Oncolytics Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
3/10/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/10/2025	ONCY Oncolytics Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00
3/3/2025	VYGR Voyager Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
2/28/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $17.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$683K	270.77	N/A	N/A	$1.56 per share	1.78
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	$0.30 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A
VYGR Voyager Therapeutics	$80.00M	2.48	$2.55 per share	1.41	$5.37 per share	0.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$41.44M	-$0.94	N/A	N/A	N/A	-6,238.17%	-73.97%	-60.40%	5/1/2025 (Estimated)
ELDN Eledon Pharmaceuticals	-$116.54M	-$2.36	N/A	N/A	N/A	N/A	-189.99%	-28.17%	5/8/2025 (Estimated)
ONCY Oncolytics Biotech	-$20.56M	-$0.30	N/A	N/A	N/A	N/A	-141.15%	-84.73%	5/8/2025 (Estimated)
VYGR Voyager Therapeutics	$132.33M	-$1.13	5.06	N/A	N/A	15.80%	8.33%	6.15%	5/12/2025 (Estimated)

Latest ONCY, ELDN, CRDF, and VYGR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	VYGR Voyager Therapeutics	-$0.35	N/A	N/A	N/A	$13.55 million	N/A
5/8/2025	Q1 2025	ELDN Eledon Pharmaceuticals	-$0.28	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	ONCY Oncolytics Biotech	-$0.09	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	CRDF Cardiff Oncology	-$0.20	N/A	N/A	N/A	$0.09 million	N/A
3/20/2025	Q4 2024	ELDN Eledon Pharmaceuticals	-$0.32	-$0.64	-$0.32	-$0.64	N/A	N/A
3/11/2025	Q4 2024	VYGR Voyager Therapeutics	-$0.35	-$0.59	-$0.24	-$0.59	$16.58 million	$4.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
ELDN Eledon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
VYGR Voyager Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	4.74	4.74
ELDN Eledon Pharmaceuticals	N/A	6.53	6.53
ONCY Oncolytics Biotech	N/A	2.99	2.99
VYGR Voyager Therapeutics	N/A	8.45	8.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
ELDN Eledon Pharmaceuticals	56.77%
ONCY Oncolytics Biotech	6.82%
VYGR Voyager Therapeutics	48.03%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.80%
ELDN Eledon Pharmaceuticals	11.70%
ONCY Oncolytics Biotech	0.10%
VYGR Voyager Therapeutics	4.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.52 million	47.15 million	Optionable
ELDN Eledon Pharmaceuticals	10	59.88 million	52.75 million	Optionable
ONCY Oncolytics Biotech	30	86.42 million	85.42 million	Not Optionable
VYGR Voyager Therapeutics	100	55.31 million	52.15 million	Optionable

ONCY, ELDN, CRDF, and VYGR Headlines

Recent News About These Companies

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

April 28 at 4:30 PM | globenewswire.com

Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $13.97

April 24, 2025 | americanbankingnews.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Buy" from Brokerages

April 22, 2025 | marketbeat.com

Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ...

April 21, 2025 | finance.yahoo.com

FY2026 Earnings Forecast for VYGR Issued By Leerink Partnrs

April 20, 2025 | marketbeat.com

Research Analysts Offer Predictions for VYGR FY2026 Earnings

April 20, 2025 | americanbankingnews.com

7 Analysts Assess Voyager Therapeutics: What You Need To Know

April 10, 2025 | nasdaq.com

Voyager Therapeutics (NASDAQ:VYGR) Receives "Buy" Rating from HC Wainwright

April 10, 2025 | marketbeat.com

Voyager updates on Alzheimer’s programs ‘compelling,’ says H.C. Wainwright

April 9, 2025 | markets.businessinsider.com

ADAR1 Capital Management LLC Acquires 86,158 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

April 9, 2025 | marketbeat.com

TD Cowen Keeps Their Buy Rating on Voyager Therapeutics (VYGR)

April 8, 2025 | markets.businessinsider.com

2VYGR : 7 Analysts Assess Voyager Therapeutics: What You Need To Know

April 8, 2025 | benzinga.com

Raymond James Financial Inc. Takes Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

April 7, 2025 | marketbeat.com

Alfred Sandrock Sells 10,885 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) Stock

April 6, 2025 | insidertrades.com

Insider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Sells 10,885 Shares of Stock

April 6, 2025 | marketbeat.com

Prudential Financial Inc. Sells 82,100 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR)

April 6, 2025 | marketbeat.com

Voyager Therapeutics Presents Promising Tau-Targeting Gene Therapy And Antibody Data At AD/PD 2025

April 2, 2025 | nasdaq.com

Voyager Therapeutics, Inc.: Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025

March 31, 2025 | finanznachrichten.de

Voyager Therapeutics announces new data from two preclinical programs

March 31, 2025 | markets.businessinsider.com

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

March 31, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR

March 19, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, ELDN, CRDF, and VYGR Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$2.78 -0.17 (-5.76%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$2.80 +0.02 (+0.72%)

As of 04/29/2025 07:02 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Eledon Pharmaceuticals NASDAQ:ELDN

$3.27 -0.01 (-0.30%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$3.27 0.00 (0.00%)

As of 04/29/2025 04:05 PM Eastern

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Oncolytics Biotech NASDAQ:ONCY

$0.59 +0.02 (+3.84%)

Closing price 04/29/2025 03:59 PM Eastern

Extended Trading

$0.59 +0.00 (+0.35%)

As of 04/29/2025 05:38 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Voyager Therapeutics NASDAQ:VYGR

$3.59 +0.06 (+1.70%)

Closing price 04/29/2025 04:00 PM Eastern

Extended Trading

$3.58 0.00 (-0.14%)

As of 04/29/2025 04:27 PM Eastern

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time